Nursing care
Argatroban and bivalirudin: aPTT titration, bleeding and organ function
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated October 2026
Short answer
Argatroban and bivalirudin are IV direct thrombin inhibitors used when heparin cannot be, most notably in heparin-induced thrombocytopenia. Argatroban is titrated to aPTT and cleared by the liver; bivalirudin is cleared largely by the kidneys and used around coronary intervention. Neither has a specific reversal agent, so bleeding surveillance and prompt protocol-based response are central.
Why heparin is replaced, and how these drugs work
In heparin-induced thrombocytopenia, antibodies activate platelets and create a high risk of clotting, so all heparin, including flushes and low molecular weight heparin, is stopped and a non-heparin anticoagulant started. Argatroban is approved for prevention and treatment of thrombosis in HIT, and bivalirudin is approved for coronary intervention including patients with HIT.
Both drugs bind thrombin directly rather than working through antithrombin, so they inhibit free and clot-bound thrombin. Argatroban binds reversibly to the active site. Bivalirudin binds the active site and a second site, and thrombin gradually cleaves it, which partly explains its short half-life of about 25 minutes with normal kidney function.
aPTT-guided titration and organ function
Argatroban is adjusted against a baseline aPTT, with a repeat sample a set time after starting and after each rate change. Follow the institutional nomogram, draw samples from the correct site and avoid sampling from the infusion line. The nurse's role is accurate timing, correct rate changes and early escalation of out-of-range results.
Argatroban is metabolised by the liver, so hepatic impairment needs lower starting rates and its effect lasts much longer. Bivalirudin is renally cleared, so infusion rates are reduced in severe kidney impairment and dialysis. Check that orders match current liver and kidney results, and report a new rise in bilirubin or creatinine during therapy.
Bleeding cues, no direct antidote and warfarin transition
Bleeding is the main adverse effect. Look for oozing at lines and puncture sites, haematuria, melaena, bruising, falling haemoglobin, back or flank pain and any neurological change. Neither drug has a specific reversal agent; idarucizumab reverses dabigatran only. Management relies on stopping the infusion, supportive care and the short half-lives, which are longer with organ impairment.
Argatroban raises the INR as well as the aPTT, so the INR is higher than warfarin alone would produce during overlap. Transition follows a specific protocol with prolonged overlap and INR checks, rather than stopping argatroban when the INR first looks therapeutic. Misreading this combined INR could leave the patient unprotected in a high-clotting-risk state.
Hold, report and handover essentials
Hold or reduce the infusion and notify the prescriber according to protocol for active bleeding, an aPTT above the upper limit, a sudden fall in haemoglobin or a new neurological change. Clarify the plan before procedures such as line insertion or surgery, as anticoagulation may need to be paused for a defined period.
At handover, report the current rate, time and result of the last aPTT, the time the next sample is due, liver and kidney results and the platelet trend. In HIT, a recovering platelet count supports the diagnosis, while new limb pain, swelling or colour change may signal thrombosis despite treatment and needs urgent review.
An original scenario on priorities
In a hypothetical case, a patient with HIT on argatroban has new liver failure, an aPTT well above range and fresh blood in the urinary catheter bag. Options are to give protamine, continue at the same rate and recheck in the morning, or stop or reduce the infusion per protocol, assess for bleeding and notify the prescriber. The last option fits the drug and the situation. Continuing unchanged until morning ignores both the out-of-range result and the visible bleeding. Liver failure explains why the drug has accumulated, which is why the rate needs urgent review.
Protamine is the wrong choice because it neutralises heparin, not direct thrombin inhibitors. Teaching while on therapy focuses on reporting bleeding and avoiding injury, and the medication record should flag heparin allergy clearly so heparin flushes or heparin-coated catheters are not used by mistake.
Sources and further reading
StatPearls: Argatroban. HIT indication, mechanism, hepatic dose reduction, aPTT monitoring, INR effect with warfarin, bleeding and absence of an antidote.
DailyMed: Bivalirudin for injection prescribing information. PCI and HIT indication, mechanism, half-life, renal clearance, bleeding and no known antidote.
StatPearls: Anticoagulation Therapy. Direct thrombin inhibitor class action, argatroban in HIT and idarucizumab being specific to dabigatran.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our dosage calculation and lab values practice questions are the closest set to what this page covers.
Common questions
Which organ matters most for argatroban dosing?
The liver. Argatroban is hepatically metabolised, so impairment needs lower rates and prolongs its effect. Bivalirudin, by contrast, depends more on the kidneys.
Can protamine reverse argatroban or bivalirudin?
No. Protamine reverses heparin. There is no specific antidote for these drugs; bleeding management relies on stopping the infusion and supportive care.
Why is the INR misleading when argatroban and warfarin overlap?
Argatroban raises the INR itself, so the combined value overstates warfarin's effect. Transition follows a defined protocol with INR checks.
More on dosage calculation and lab values